Cohen Marta C, Ashok Dhandapani, Gell Mark, Bishop John, Walker Jenny, Thomson Mike, Al-Adnani Mudher
Department of Histopathology, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield, UK.
Pediatr Dev Pathol. 2009 Mar-Apr;12(2):116-26. doi: 10.2350/08-03-0436.1. Epub 2008 Nov 13.
We describe the clinical, endoscopic, and histological features of all cases of Barrett's esophagus (BE) diagnosed at our institution between 2000 and 2007 following the criteria of the British Society of Gastroenterology. This society defines BE as a segment of columnar metaplasia (CLO) (whether intestinalized or not) of any length, visible endoscopically above the gastroesophageal junction and confirmed histologically. The diagnosis was challenged after immunostaining for Cdx2 (marker of intestinal differentiation). Information was collected with respect to age, symptoms, treatment, and endoscopic and histological features. Twelve children (10 males and 2 females) with a median age of 11.7 (2 to 17) years had been diagnosed with CLO-BE. Histology confirmed BE in 31 of 38 endoscopies. The initial diagnosis was reviewed according to Cdx2 results in 10 of 12 patients: Cdx2 strongly expressed in 4 cases with intestinal metaplasia (the diagnosis of BE was maintained); was negative in 4 other patients with "CLO" mucosa (reviewed diagnosis was that of expansion of the gastric cardia into the distal esophagus); and 2 patients had occasional Cdx2-positive cells showing cardia-type mucosa with goblet cells (early BE?). The estimated prevalence of CLO-BE in the pediatric population of South Yorkshire (United Kingdom) is 0.0024%, 0.8% in children referred for endoscopy and 5.5% in the children with reflux esophagitis. Characterization of the BE and confirmation of intestinal differentiation may have prognostic implications that can impact the surveillance program. Our results showed that intestinal differentiation as demonstrated with Cdx2 was only seen if goblet cells were present. A consensus definition and further studies to understand the molecular mechanisms involved in the development of BE at this age are needed.
我们描述了2000年至2007年间在我们机构按照英国胃肠病学会标准诊断的所有巴雷特食管(BE)病例的临床、内镜和组织学特征。该学会将BE定义为任何长度的柱状化生(CLO)(无论是否肠化生)节段,在内镜下可见于胃食管交界处上方,并经组织学证实。在对Cdx2(肠分化标志物)进行免疫染色后,对诊断提出了质疑。收集了有关年龄、症状、治疗以及内镜和组织学特征的信息。12名儿童(10名男性和2名女性)被诊断为CLO-BE,中位年龄为11.7岁(2至17岁)。38次内镜检查中有31次经组织学证实为BE。根据Cdx2结果对12例患者中的10例进行了初步诊断复查:4例肠化生患者Cdx2强表达(维持BE诊断);另外4例“CLO”黏膜患者Cdx2阴性(复查诊断为胃贲门向食管远端扩展);2例患者偶尔有Cdx2阳性细胞,显示为带有杯状细胞的贲门型黏膜(早期BE?)。英国南约克郡儿科人群中CLO-BE的估计患病率为0.0024%,接受内镜检查的儿童中为0.8%,反流性食管炎儿童中为5.5%。BE的特征描述和肠分化的确认可能具有预后意义,会影响监测方案。我们的结果表明,只有存在杯状细胞时才会出现Cdx2所显示的肠分化。需要一个共识定义并进行进一步研究,以了解该年龄段BE发生发展所涉及的分子机制。